Independent register of U.S. FDA drug recalls · updated Oct 10, 2026
RxRecalls Get alerts

Is Aripiprazole recalled?

Yes — there is an active recall. 7 ongoing FDA recalls mention Aripiprazole (29 total). Check the affected lots below.

Most common reason: cGMP deviation (10 of these recalls)

Recalls are matched by product description. A recall usually affects specific lots, not every package of Aripiprazole. “Active” means an FDA recall is still ongoing; “closed” means it was terminated or completed. Checked against openFDA on Oct 10, 2026.

Aripiprazole recalls in 2026

1 initiated in 2026, 29 in total — newest first
Class II · Moderate risk

Aripiprazole Tablets USP

Product Mix-Up: A bottle containing Voriconazole Tablets 50 mg was labelled and distributed as Aripiprazole Tablets USP 30 mg.

Ongoing Labeling / mix-up Ajanta Pharma USA Inc NDC 27241-056-03 D-0594-2026
Class III · Low risk

Abilify (aripiprazole)

Cross Contamination with Other Products

Ongoing Cross-contamination Second Tokushima Factory, Otsuka Pharmaceutical Co., Ltd. NDC 59148-011-13 D-0469-2024
Class III · Low risk

Abilify (aripiprazole)

Cross Contamination with Other Products

Ongoing Cross-contamination Second Tokushima Factory, Otsuka Pharmaceutical Co., Ltd. NDC 59148-009-13 D-0468-2024
Class III · Low risk

Abilify (aripiprazole)

Cross Contamination with Other Products

Ongoing Cross-contamination Second Tokushima Factory, Otsuka Pharmaceutical Co., Ltd. NDC 59148-008-13 D-0467-2024
Class III · Low risk

Abilify (aripiprazole)

Cross Contamination with Other Products

Ongoing Cross-contamination Second Tokushima Factory, Otsuka Pharmaceutical Co., Ltd. NDC 59148-007-13 D-0466-2024
Class II · Moderate risk

Aripiprazole Tablets

CGMP Deviations: recalling drug products following an FDA inspection.

Terminated cGMP deviation Accord Healthcare, Inc. NDC 16729-283-10 D-0370-2023
Class II · Moderate risk

Aripiprazole Tablets

CGMP Deviations: recalling drug products following an FDA inspection.

Terminated cGMP deviation Accord Healthcare, Inc. NDC 16729-282-10 D-0369-2023
Class II · Moderate risk

Aripiprazole Tablets

CGMP Deviations: recalling drug products following an FDA inspection.

Terminated cGMP deviation Accord Healthcare, Inc. NDC 16729-281-10 D-0368-2023
Class II · Moderate risk

Aripiprazole Tablets

CGMP Deviations: recalling drug products following an FDA inspection.

Terminated cGMP deviation Accord Healthcare, Inc. NDC 16729-280-10 D-0367-2023
Class II · Moderate risk

Aripiprazole Tablets

CGMP Deviations: recalling drug products following an FDA inspection.

Terminated cGMP deviation Accord Healthcare, Inc. NDC 16729-279-10 D-0366-2023
Class II · Moderate risk

Aripiprazole Tablets

CGMP Deviations: recalling drug products following an FDA inspection.

Terminated cGMP deviation Accord Healthcare, Inc. NDC 16729-278-10 D-0365-2023
Class II · Moderate risk

Aripiprazole Tablets

Failed dissolution specifications: OOS for dissolution at the 12-month stability time point.

Terminated Dissolution failure Apotex Corp. NDC 60505-2676-8 D-1285-2022
Class II · Moderate risk

Aripiprazole Tablets

CGMP Deviations: Products were exposed to temperatures outside of the products labeled storage conditions.

Terminated Temperature excursion Cardinal Healthcare D-0167-2024
Class II · Moderate risk

Aripiprazole Tablets

Failed Dissolution Specifications: Out of specification for dissolution.

Terminated Dissolution failure The Harvard Drug Group NDC 0904-6512-04 D-0114-2021
Class II · Moderate risk

Aripiprazole Tablets

FAILED DISSOLUTION SPECIFICATIONS: Possibility of out-of-specification (OOS) dissolution limits for the remaining shelf life of the Aripiprazole Tablets

Terminated Dissolution failure Golden State Medical Supply Inc. NDC 60429-449-30 D-0112-2021
Class II · Moderate risk

Aripiprazole Tablets

Failed Dissolution Specifications: Out of specification for dissolution.

Terminated Dissolution failure Apotex Corp. NDC 60505-2675-8 D-0106-2021
Class II · Moderate risk

Aripiprazole Tablets

Labeling: Label mix up: Bottles labeled as aripiprazole 2 mg, 30 count had aripiprazole 5 mg tablets, 100 count.

Terminated Labeling / mix-up Alembic Pharmaceuticals Limited NDC 62332-097-30 D-1341-2020
Class III · Low risk

treatNOW ABILIFY

Labeling Not Elsewhere Classified: Physician sample kits/cartons of treatNOW Abilify are mislabeled. Product name is misspelled, storage instructions are missing and contents of kits may be incorrectly labeled on the outer packaging of the co-packaged kit.

Terminated Labeling / mix-up Otsuka Pharmaceutical Development & Commercialization, Inc. D-0018-2019
Class III · Low risk

treatNOW ABILIFY

Labeling Not Elsewhere Classified: Physician sample kits/cartons of treatNOW Abilify are mislabeled. Product name is misspelled, storage instructions are missing and contents of kits may be incorrectly labeled on the outer packaging of the co-packaged kit.

Terminated Labeling / mix-up Otsuka Pharmaceutical Development & Commercialization, Inc. D-0017-2019
Class II · Moderate risk

Aripiprazole Tablets

CGMP Deviations: lot made with active pharmaceutical ingredient that did not meet all its intended specifications.

Terminated cGMP deviation American Health Packaging NDC 60687-179-11 D-0595-2018
Class II · Moderate risk

Aripiprazole Tablets

CGMP Deviations: lot made with active pharmaceutical ingredient that did not meet all its intended specifications.

Terminated cGMP deviation Hetero Labs, Ltd. - Unit III NDC 31722-827-30 D-0594-2018
Class III · Low risk

Aripiprazole Tablets

Superpotent Drug; out of specification results for assay (manufacturer)

Terminated Wrong potency / content The Harvard Drug Group NDC 0904-6509-04 D-0692-2017